Humphreys Keith
Clin Schizophr Relat Psychoses. 2017 Spring;11(1):49-57. doi: 10.3371/1935-1232-11.1.49.
Treatment research studies employ criteria that determine which patients are eligible to participate and which are not. When such exclusion criteria produce a treatment research sample that is a small and unrepresentative subset of all patients with a particular disease, clinicians may be hesitant to apply the research results in front-line clinical practice. Accordingly, the present paper reviews the English-language literature on exclusion criteria in schizophrenia treatment research and draws initial conclusions about their impact. Empirically derived estimates of the rate of exclusion vary widely (31.0-98.2%), but the best available evidence suggests that about 4 in 5 patients with schizophrenia would be ineligible to enroll in a typical treatment research study. Women are particularly likely to be excluded from schizophrenia treatment research, which is problematic from both a clinical and social justice viewpoint. Excluded patients also tend to be older than eligible patients, and, though it has been examined in only a few studies, they also tend to have more severe problems at baseline and different outcomes over time than patients who are allowed to participate in research. More limited use of exclusion criteria in schizophrenia treatment research would be beneficial in terms of increasing generalizability, but would also potentially involve costs, particularly a need for larger samples. More modest steps that would improve treatment outcome research reports include requiring a full description of the rationale for, and nature of, any exclusion criteria, and, having a designated place in the discussion section which draws attention to the proper scope of generalization.
治疗研究采用标准来确定哪些患者有资格参与研究,哪些没有。当这些排除标准所产生的治疗研究样本只是患有特定疾病的所有患者中的一个小的、缺乏代表性的子集时,临床医生可能会犹豫是否要将研究结果应用于一线临床实践。因此,本文回顾了关于精神分裂症治疗研究中排除标准的英文文献,并就其影响得出初步结论。根据经验得出的排除率估计差异很大(31.0% - 98.2%),但现有最佳证据表明,约五分之四的精神分裂症患者没有资格参加典型的治疗研究。女性尤其容易被排除在精神分裂症治疗研究之外,从临床和社会公正的角度来看,这都是有问题的。被排除的患者往往比符合条件的患者年龄更大,而且,尽管只有少数研究对此进行了考察,但与被允许参与研究的患者相比,他们在基线时往往有更严重的问题,随着时间推移也会有不同的结果。在精神分裂症治疗研究中更有限地使用排除标准,在提高普遍性方面将是有益的,但也可能涉及成本,特别是需要更大的样本。更适度的措施,即改善治疗结果研究报告,包括要求全面描述任何排除标准的理由和性质,并在讨论部分指定一个位置,提请注意适当的推广范围。